We are live on ! Find out more
VNDA icon

Vanda Pharmaceuticals
VNDA

125 hedge funds and large institutions have $621M invested in Vanda Pharmaceuticals in 2017 Q4 according to their latest regulatory filings, with 13 funds opening new positions, 49 increasing their positions, 42 reducing their positions, and 25 closing their positions.

New
Increased
Maintained
Reduced
Closed

17% more repeat investments, than reductions

Existing positions increased: 49 | Existing positions reduced: 42

2.42% more ownership

Funds ownership: 88.55% → 90.97% (+2.4%)

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

9% less funds holding

Funds holding: 137 → 125 (-12)

13% less capital invested

Capital invested by funds: $711M → $621M (-$89.8M)

48% less first-time investments, than exits

New positions opened: 13 | Existing positions closed: 25

92% less call options, than puts

Call options by funds: $768K | Put options by funds: $9.36M

Holders
125
Holders Change
-12
Holders Change %
-8.76%
% of All Funds
2.84%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.05%
New
13
Increased
49
Reduced
42
Closed
25
Calls
$768K
Puts
$9.36M
Net Calls
-$8.59M
Net Calls Change
-$13.9M

Top Buyers

Rank Fund Capital Flow
1
AC
Armistice Capital
New York
+$17M
2
SCM
Stonepine Capital Management
Oregon
+$8.68M
3
State Street
State Street
Massachusetts
+$7.22M
4
ACA
Avoro Capital Advisors
New York
+$6.24M
5
Macquarie Group
Macquarie Group
Australia
+$5.62M

Top Sellers

Rank Fund Capital Flow
1
Citadel Advisors
Citadel Advisors
Florida
-$9.78M
2
Invesco
Invesco
Georgia
-$7.34M
3
Millennium Management
Millennium Management
New York
-$4.65M
4
RCM
RA Capital Management
Massachusetts
-$4.37M
5
Principal Financial Group
Principal Financial Group
Iowa
-$3.83M
Name Holding Trade Value Shares
Change 		Change in
Stake
Invesco
126
Invesco
Georgia
– -$7.34M -409,835 Closed
RCM
127
RA Capital Management
Massachusetts
– -$4.37M -243,971 Closed
Principal Financial Group
128
Principal Financial Group
Iowa
– -$3.83M -213,898 Closed
QIM
129
Quantitative Investment Management
Virginia
– -$2.62M -146,200 Closed
GAM
130
Gotham Asset Management
New York
– -$2.54M -142,159 Closed
AI
131
Axiom Investors
Connecticut
– -$2.46M -137,167 Closed
3C
132
361 Capital
Colorado
– -$2.14M -119,554 Closed
First Trust Advisors
133
First Trust Advisors
Illinois
– -$1.25M -69,942 Closed
ARTA
134
A.R.T. Advisors
New York
– -$1.07M -59,900 Closed
CCI
135
Columbus Circle Investors
– -$1.03M -57,310 Closed
NFA
136
Nationwide Fund Advisors
Ohio
– -$735K -41,085 Closed
FRM
137
Fox Run Management
Connecticut
– -$696K -38,900 Closed
MCM
138
Matarin Capital Management
New York
– -$682K -38,075 Closed
PA
139
Perceptive Advisors
New York
– -$649K -36,232 Closed
SAM
140
Shell Asset Management
Netherlands
– -$540K -30,168 Closed
Federated Hermes
141
Federated Hermes
Pennsylvania
– -$450K -25,131 Closed
CONA
142
Capital One National Association
New York
– -$338K -18,890 Closed
GS
143
Gagnon Securities
New York
– -$325K -18,131 Closed
DTL
144
Dynamic Technology Lab
Singapore
– -$278K -15,521 Closed
BA
145
Boston Advisors
Massachusetts
– -$278K -15,515 Closed
SG Americas Securities
146
SG Americas Securities
New York
– -$158K -8,828 Closed
CG
147
Cutler Group
California
– -$20.8K -1,400 Closed
LTFS
148
Ladenburg Thalmann Financial Services
Florida
– -$20K -1,134 Closed
IA
149
IFP Advisors
Florida
– -$18K -1,000 Closed
WEC
150
Winslow Evans & Crocker
Massachusetts
– -$1.25K -70 Closed
2 3 4 5
6

VNDA Hedge Fund Activity: Q4 2017 in Review

125 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in Vanda Pharmaceuticals (VNDA) for Q4 2017, worth a combined $621M — down 13% from $711M a quarter earlier.

Sellers outnumbered buyers: 25 funds closed out of VNDA and 13 opened new positions — a net loss of 12 holders — while 42 trimmed existing stakes and 49 added.

The largest buyer was Armistice Capital, adding an estimated $17M. The largest seller was Citadel Advisors, cutting an estimated $9.78M.

  • 125 institutional investors held Vanda Pharmaceuticals (VNDA) as of Q4 2017, down from 137 in Q3 2017.
  • Funds reported $621M of Vanda Pharmaceuticals stock for Q4 2017, down 13% quarter-over-quarter.
  • 13 funds opened new Vanda Pharmaceuticals positions in Q4 2017 and 25 closed out, a net change of -12 holders.
  • The largest Vanda Pharmaceuticals buyer in Q4 2017 was Armistice Capital, an estimated $17M added.
  • The largest Vanda Pharmaceuticals seller in Q4 2017 was Citadel Advisors, an estimated $9.78M sold.

Based on aggregated 13F filings for Q4 2017.